Abstract
T cell responses were less functional and persisted in an exhausted state in chronic HIV infection. Even in the early phase of HIV infection, the dysfunction of HIV-specific T cells can be observed in rapid progressors, but the underlying mechanisms are not fully understood. Cytokines play a central role in regulating T cell function. In this study, we sought to elucidate whether the IL-33/ST2 axis plays a role in the regulation of T cell function in HIV infection. We found that the level of IL-33 was upregulated in early HIV-infected patients compared with that in healthy controls and has a trend associated with disease progression. In vitro study shows that IL-33 promotes the expression of IFN-γ by Gag stimulated CD4+ and CD8+ T cells from HIV-infected patients to a certain extent. However, soluble ST2 (sST2), a decoy receptor of IL-33, was also increased in early HIV infected patients, especially in those with progressive infection. We found that anti-ST2 antibodies attenuated the effect of IL-33 to CD4+ and CD8+ T cells. Our data indicates that elevated expression of IL-33 in early HIV infection has the potential to enhance the function of T cells, but the upregulated sST2 weakens the activity of IL-33, which may indirectly contribute to the dysfunction of T cells and rapid disease progression.
Introduction
In the fight against HIV, T cells serve as the primary defense. However, chronic infection often leads to a state of "exhaustion," where these cells become less effective at neutralizing the virus. While this decline is well-documented in late-stage disease, researchers are investigating why T cell dysfunction begins even in the earliest phases of infection, particularly in "rapid progressors."
A recent study published in Frontiers in Immunology focuses on the IL-33/ST2 axis. IL-33 is an "alarmin," a signaling protein released by damaged cells to alert the immune system. It normally binds to the ST2L receptor on T cells to stimulate a robust response. However, the body also produces a soluble version of this receptor, sST2, which acts as a "decoy." It circulates in the blood and binds to IL-33 before it can reach a T cell, effectively neutralizing the immune signal.
Methods
The research team studied 44 treatment-naive patients in the early stages of HIV infection (EHI) and compared them to 20 healthy controls (HC).
- Plasma Analysis: ELISA kits were used to measure the concentrations of IL-33 and sST2 in the blood.
- Cellular Assays: CD4+ and CD8+ T cells were isolated and stimulated with HIV-specific Gag antigens.
- Functional Testing: Flow cytometry and ELISPOT assays measured Interferon-gamma (IFN-γ) production following treatment with recombinant IL-33.
- Pathway Blocking: Anti-ST2 antibodies were used in vitro to mimic the inhibitory effect of the sST2 decoy.
Results
IL-33 as an Early Immune Signal
The study found that plasma IL-33 levels were significantly higher in EHI patients (~16 pg/mL) compared to healthy controls (~14 pg/mL, $p=0.002$). As shown in Figure 1, these levels correlate positively with viral load ($r = 0.315, p = 0.037$), suggesting the body increases IL-33 production as an initial response to viral replication.
The Decoy Sabotage
While IL-33 was shown to nearly triple the percentage of IFN-γ producing CD8+ T cells in response to HIV antigens in vitro, this benefit is countered by elevated sST2. Patients with early HIV infection showed significantly higher sST2 levels (~25.6 ng/mL) compared to controls (~20.2 ng/mL, $p=0.020$).
Crucially, higher sST2 levels correlated with higher viral loads and lower CD4+ T cell counts (Figure 4). This suggests that sST2 acts as a marker for disease progression by neutralizing the immune-boosting potential of IL-33. The researchers confirmed this mechanism by using anti-ST2 antibodies, which successfully "turned off" the benefits of IL-33, mimicking the dysfunction seen in patients.
Discussion and Conclusion
The findings reveal a molecular "tug-of-war" in early HIV infection. While the body attempts to ramp up immune defenses via IL-33, the simultaneous overproduction of the decoy receptor sST2 inadvertently sabotages these efforts. This mechanism contributes to early T cell exhaustion and rapid disease progression.
While the study is cross-sectional and focused on blood plasma rather than tissue-specific dynamics, it identifies the IL-33/ST2 axis as a critical factor in HIV pathogenesis. These results provide a foundation for future research into whether blocking the sST2 decoy could help restore T cell function and improve outcomes for HIV patients.
Summary updated